Two new drugs, developed by a Taiwanese company for the treatment of schizophrenia and designated by the U.S. Food and Drug Administration (FDA) as breakthrough therapy, will undergo late stage trials this year, according to the company's founder and CEO.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan shares open lower
04/25/2024 09:13 AM - Cross-Strait
New Taipei ward chief indicted in alleged subsidized China trip case
04/24/2024 10:51 PM - Cross-Strait
Matsu Islands seek to return ocean waste to China
04/24/2024 10:17 PM - Society
Taichung Japanese barbecue restaurant suspected of using expired meat
04/24/2024 09:45 PM - Society
Rescue of flying fox marks big step in megabat conservation: Agency
04/24/2024 09:39 PM